Page last updated: 2024-12-05

iotrolan

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Iotrolan is a nonionic iodinated contrast agent used in diagnostic imaging. It is a triiodinated derivative of benzoic acid with a molecular weight of 789.1 g/mol. Iotrolan is administered intravenously and is rapidly excreted by the kidneys. It is a highly effective contrast agent for enhancing the visualization of blood vessels, organs, and other structures in various imaging modalities, including computed tomography (CT) and magnetic resonance imaging (MRI). Iotrolan is widely studied and used due to its excellent safety profile, high contrast enhancement properties, and rapid clearance from the body. Its synthesis involves a complex multi-step process that begins with the reaction of 3-amino-4-hydroxybenzoic acid with iodine and then proceeds through several chemical modifications. The precise mechanism of contrast enhancement provided by iotrolan is attributed to its high iodine content, which interacts with X-rays and magnetic fields used in imaging techniques. Iotrolan plays a crucial role in medical diagnosis by allowing clinicians to visualize anatomical structures and identify abnormalities in a variety of conditions, such as stroke, cancer, and vascular diseases.'

iotrolan: nonionic, isotonic contrast medium designed for intrathecal use; RN given refers to cpd without isomeric designation; DL-3-117 refers to stereoisomer; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID3738
CHEMBL ID1200555
CHEBI ID31715
SCHEMBL ID25535
MeSH IDM0103391

Synonyms (61)

Synonym
dl-3117
isovist
iotrolan
iotrol
sh-l-437d
5,5'-[(1,3-dioxopropane-1,3-diyl)bis(methylimino)]bis{n,n'-bis[2,3-dihydroxy-1-(hydroxymethyl)propyl]-2,4,6-triiodobenzene-1,3-dicarboxamide}
dl 3-117
5,5'-(malonylbis(methylimino))bis(n,n'-bis(2,3-dihydroxy-1-(hydroxymethyl)propyl)-2,4,6-triiodoisophthalamide)
1,3-benzenedicarboxamide, 5,5'-((1,3-dioxo-1,3-propanediyl)bis(methylimino))bis(n,n'-bis(2,3-dihydroxy-1-(hydroxymethyl)propyl)-2,4,6-triiodo-
iotrovist
zk 39482
iotrolum [inn-latin]
sh 437
iotrolanum [latin]
isovist 300 (tn)
iotrolan (jan/usan/inn)
D01714
79770-24-4
isovist 300
zk-39-482
zk-39482
zk 39 482
CHEMBL1200555
2,4,6-triiodo-5-[methyl-[3-oxo-3-[2,4,6-triiodo-n-methyl-3,5-bis(1,3,4-trihydroxybutan-2-ylcarbamoyl)anilino]propanoyl]amino]-1-n,3-n-bis(1,3,4-trihydroxybutan-2-yl)benzene-1,3-dicarboxamide
osmovist
1,3-benzenedicarboxamide, 5,5'-((1,3-dioxo-1,3-propanediyl)bis(methylimino))bis(n,n'-bis(2,3-dihydroxy-1-(hydroxymethyl)propyl))-2,4,6-triiodo-
osmovist 190
16fl47b687 ,
iotrolanum
unii-16fl47b687
iotrolan [usan:inn:ban:jan]
iotrolum
osmovist 240
iotrolan(isovist)
SCHEMBL25535
iotrolan [mi]
iotrolan [usan]
iotrolan [inn]
iotrolan [ep monograph]
iotrolan [who-dd]
iotrolan [vandf]
iotrolan [jan]
iotrolan [orange book]
iotrolan [mart.]
DTXSID0023165 ,
CHEBI:31715
FT-0754152
Q6064149
DB09487
compound zk 39482
iotrolan for system suitability
2,4,6-triiodo-5-{n-methyl-2-[methyl({2,4,6-triiodo-3,5-bis[(1,3,4-trihydroxybutan-2-yl)carbamoyl]phenyl})carbamoyl]acetamido}-n1,n3-bis(1,3,4-trihydroxybutan-2-yl)benzene-1,3-dicarboxamide
EN300-19767814
iotrolan (mart.)
iotrolanum (latin)
dtxcid303165
iotrolan (ep monograph)
iotrolum (inn-latin)
v08ab06
CS-0031118
HY-107992

Research Excerpts

Overview

Iotrolan is a water-soluble and nonionic dimeric contrast medium. Has potential greater safety for use in HSG than Lipiodol. composed of C37 H48 I6 N6 O18.

ExcerptReferenceRelevance
"Iotrolan is a dimeric, nonionic, iodinated compound which is distinguished by its ability to form dense, non-viscous gradients of low osmolarity."( Properties and applications of a new type of iodinated gradient medium.
Bendixen, B; Rickwood, D, 1994
)
1.01
"Iotrolan, which is a water-soluble and nonionic dimeric contrast medium, has potential greater safety for use in HSG than Lipiodol."( Safety and pharmacokinetics of iotrolan in hysterosalpingography. Retention and irritability compared with Lipiodol.
Azuma, H; Ishida, K; Iwai, K; Miyamoto, Y; Miyazawa, T; Tsujimoto, T; Uchimoto, R, 1995
)
2.02
"Iotrolan is a non-ionic contrast media of dimer type, composed of C37 H48 I6 N6 O18."( [A case of Iotrolan encephalopathy].
Goto, H; Hosoya, T; Suga, T; Yoshioka, K, 1996
)
1.41
"Iotrolan is a nonionic dimeric CM and has a lower osmotic effect in the tubules than the ionic dimeric CM and the monomeric CM when given in iodine equivalent doses."( Influence of contrast media on single nephron glomerular filtration rate in rat kidney. A comparison between diatrizoate, iohexol, ioxaglate, and iotrolan.
Erikson, U; Hansell, P; Nygren, A; Ueda, J, 1992
)
1.21
"Iotrolan is a new nonionic, dimeric contrast medium that is distinguished by its special physicochemical and low chemotoxic properties. "( Iotrolan versus iopamidol: a controlled, multicenter, double-blind study of lumbar and direct cervical myelography.
Klotz, E; Ringel, K; Wenzel-Hora, BI, 1989
)
3.16

Effects

Iotrolan has slower flow through catheters and capillaries than that of Iopamidol because of its higher viscosity. It has a lower osmotic potential than the other CM when given in equivalent iodine doses.

ExcerptReferenceRelevance
"Iotrolan has a lower osmotic potential than the other CM when given in equivalent iodine doses."( Effect of intravenous contrast media on proximal and distal tubular hydrostatic pressure in the rat kidney.
Hansell, P; Nygren, A; Ueda, J; Ulfendahl, HR, 1993
)
1.01
"Iotrolan has slower flow through catheters and capillaries than that of Iopamidol because of its higher viscosity."( [Experimental study on vascular permeability and hemodynamics of nonionic dimeric contrast media (Iotrolan): a comparison to nonionic monomer on dynamic CT and angiography].
Hasegawa, Y; Hirota, S; Kono, M; Kuwata, Y; Matsumoto, S; Murakami, T; Sako, M; Sugimoto, K; Tomita, M, 1994
)
1.23
"Iotrolan has a lower osmotic potential than the other CM when given in equivalent iodine doses."( Effect of intravenous contrast media on proximal and distal tubular hydrostatic pressure in the rat kidney.
Hansell, P; Nygren, A; Ueda, J; Ulfendahl, HR, 1993
)
1.01
"Iotrolan has no 2-deoxy-glucose structure."( [A case of Iotrolan encephalopathy].
Goto, H; Hosoya, T; Suga, T; Yoshioka, K, 1996
)
1.41

Actions

Iotrolan has slower flow through catheters and capillaries than that of Iopamidol because of its higher viscosity. It has a lower osmotic potential than the other CM when given in equivalent iodine doses.

ExcerptReferenceRelevance
"Iotrolan has slower flow through catheters and capillaries than that of Iopamidol because of its higher viscosity."( [Experimental study on vascular permeability and hemodynamics of nonionic dimeric contrast media (Iotrolan): a comparison to nonionic monomer on dynamic CT and angiography].
Hasegawa, Y; Hirota, S; Kono, M; Kuwata, Y; Matsumoto, S; Murakami, T; Sako, M; Sugimoto, K; Tomita, M, 1994
)
1.23
"Iotrolan has a lower osmotic potential than the other CM when given in equivalent iodine doses."( Effect of intravenous contrast media on proximal and distal tubular hydrostatic pressure in the rat kidney.
Hansell, P; Nygren, A; Ueda, J; Ulfendahl, HR, 1993
)
1.01

Toxicity

ExcerptReferenceRelevance
" The cats were also checked for postmyelographic adverse effects for at least 3 h after their complete recovery from anaesthesia."( Absence of postmyelographic adverse effects and high radiographic resolution of iotrolan used in the cervical myelography for the clinically normal cat: an open-placebo controlled study.
Dessiris, A; Galatos, A; Koutinas, A; Moustardas, N; Patsikas, MN; Polizopoulou, Z; Tzegas, S, 1999
)
0.53
"To prospectively evaluate adverse events (AEs) in patients who underwent nonionic monomeric or dimeric contrast media-enhanced computed tomography (CT) and to compare these effects with AEs in patients who underwent unenhanced CT."( Adverse events after unenhanced and monomeric and dimeric contrast-enhanced CT: a prospective randomized controlled trial.
Böhm, I; Hübner-Steiner, U; Kuhl, CK; Schild, HH; Speck, U, 2006
)
0.33
" Both contrast agents were safe in that no severe AEs and only a few moderate AEs were observed."( Adverse events after unenhanced and monomeric and dimeric contrast-enhanced CT: a prospective randomized controlled trial.
Böhm, I; Hübner-Steiner, U; Kuhl, CK; Schild, HH; Speck, U, 2006
)
0.33

Pharmacokinetics

ExcerptReferenceRelevance
"In man Iotrolan is distributed in the extravascular space after intravenous injection with a half-life of about 11 minutes, the elimination half-life being about 108 minutes."( Pharmacokinetics of iotrolan after intravenous injection into healthy volunteers.
Mützel, W; Scholz, P; Staks, T; Weinmann, HJ, 1989
)
1.06
" Conversely, Lipiodol was excreted into the urine, had a half-life of 50 days, and was retained for more than 21 days in the abdomen."( Safety and pharmacokinetics of iotrolan in hysterosalpingography. Retention and irritability compared with Lipiodol.
Azuma, H; Ishida, K; Iwai, K; Miyamoto, Y; Miyazawa, T; Tsujimoto, T; Uchimoto, R, 1995
)
0.58
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
organic molecular entityAny molecular entity that contains carbon.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (206)

TimeframeStudies, This Drug (%)All Drugs %
pre-199058 (28.16)18.7374
1990's112 (54.37)18.2507
2000's33 (16.02)29.6817
2010's3 (1.46)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 23.35

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index23.35 (24.57)
Research Supply Index5.62 (2.92)
Research Growth Index4.30 (4.65)
Search Engine Demand Index29.35 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (23.35)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials45 (19.48%)5.53%
Reviews8 (3.46%)6.00%
Case Studies13 (5.63%)4.05%
Observational0 (0.00%)0.25%
Other165 (71.43%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]